VANCOUVER - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed a collaborative agreement with Vanderbilt University to study patients enrolled in Vanderbilt’s Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. The agreement focuses on the continued development of Sirius’ pharmacogenomic diagnostic. The diagnostic is intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris (R)) in patients with severe sepsis at high risk of death.
“Vanderbilt’s involvement in the registration trial of activated Protein C makes Vanderbilt the perfect institution to continue further development of a genetic diagnostic for this drug,” commented Dr. Brad Popovich, President and CEO of Sirius Genomics. “We are thrilled to be working with such a credible research and medical institution.”
“Working with Sirius Genomics will move biomarker research in sepsis closer to the clinic and ultimately lead to improved patient care in the ICU. We are excited to be a part of this research effort,” stated Dr. Lorraine Ware, the Principal Investigator of VALID.
Financial terms of the agreement were not disclosed.
About Vanderbilt University Department of Medicine:
medicine.mc.vanderbilt.edu
The Department of Medicine at Vanderbilt University has over 585 faculty assigned to 12 traditional divisions and several interdisciplinary research centers. The faculty serves both patient care and biomedical discovery with unrestrained excellence. The Allergy, Pulmonary, & Critical Care Medicine Division within this department has a longstanding interest and scientific leadership in ARDS, sepsis, and Intensive Care Medicine, and has spearheaded many major clinical trials in ICU management. Active research programs in this area include cognitive outcomes in critical illness, ventilator management, biomarkers of lung injury, and nutrition in the ICU.
About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company’s first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
For further information: Dr. Brad Popovich, President and CEO, Sirius Genomics, +1-604-484-7195, bpopovich@siriusgenomics.com
Source: Sirius Genomics Inc.
For further information: Dr. Brad Popovich, President and CEO, Sirius Genomics, +1-604-484-7195, bpopovich at siriusgenomics.com
Related Press Releases
SGI President Patrinos Co-Authors Proposals on International Policies to Reduce Global Greenhouse Gas EmissionsAugust 19th, 2009 LA JOLLA, California -
To aid in reducing global greenhouse gas emissions and help solve the complex issues of climate change, two researchers have published energy and technology policy recommendations. Co-authors Aristides A.N.
Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic AlgaeJuly 13th, 2009 LA JOLLA, California -
Synthetic Genomics Inc. (SGI), a privately held company applying genomic-driven commercial solutions to address a variety of global challenges including energy and the environment, announced today a multi-year research and development agreement with ExxonMobil Research and Engineering Company (EMRE) to develop next generation biofuels using photosynthetic algae.
Sirius Genomics Announces New Collaboration With Assistance Publique-Hopitaux de ParisJuly 12th, 2009 VANCOUVER, Canada - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed a collaborative agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris (R)) in patients with severe sepsis at high risk of death.
ICON Announces Collaboration to Develop New Translational Medicine Unit at Purpose-built Hospital Facility in ManchesterJune 15th, 2009 DUBLIN - New Facility Part of Ambitious Expansion Plans at Central Manchester University Hospitals Foundation Trust Campus
ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a collaborative agreement with the Central Manchester University Hospitals Foundation (CMFT) to develop a purpose built translational medicine facility. The new facility will form part of an ambitious expansion plan being undertaken by Central Manchester University Hospitals Foundation Trust (CMFT) to develop the existing Manchester Royal Infirmary (MRI) campus.
Sirius Genomics Announces 2009 Board of DirectorsJune 7th, 2009 VANCOUVER - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that it has elected its 2009 Board of Directors at its recent Annual General Meeting. The six-member Board consists of: Dr.
Advance in Bowel Cancer Test ResearchJune 4th, 2009 SYDNEY - Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls. Being presented today at the Digestive Disease Week conference in Chicago, the preliminary findings are the result of a collaborative study - involving CSIRO, Flinders University and Australian healthcare company, Clinical Genomics Pty Ltd - designed to develop an improved screening/diagnostic test for detecting bowel cancer and significant pre-cancer lesions.
Roxette Reunion Special Hosted By Per Gessle to Air on Nordic Rox on SIRIUS XM's The Spectrum ChannelMay 27th, 2009 NEW YORK - The Spectrum's "Nordic Rox" weekly show to offer listeners a rare opportunity to hear live performances of Roxette's biggest songs
- The Roxette reunion special to feature a special broadcast of Roxette's Per Gessle's recent London performance
- Only U.S. airing of the Per and Marie on-stage reunion
- Additional Roxette programming to air on various SIRIUS XM music channels
SIRIUS XM Radio (Nasdaq: SIRI) announced today that it will broadcast a Roxette reunion special, including an exclusive airing of the Swedish pop group's Per Gessle's recent performance in London, on its Spectrum channel, SIRIUS channel 18 and XM channel 45, on Sunday, May 31 at 8:00 pm ET.
Agendia Opens CLIA-Registered U.S. Genomics LaboratoryMay 25th, 2009 HUNTINGTON BEACH, California and AMSTERDAM - Agendia Increases U.S. Footprint with Domestic Executive Team and Operations
Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S.
Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer TestingApril 28th, 2009 SYDNEY - To Receive Milestone Payments from Quest Diagnostics
Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based biomarkers associated with early onset of colorectal cancer. Clinical Genomics was awarded the payments after successfully achieving key research and development goals.
Further 100 Million Euros Allocated to Netherlands-Based R&D Targeting the Early Diagnosis and Treatment of DiseaseMarch 9th, 2009 EINDHOVEN, The Netherlands - The Center for Translational Molecular Medicine (CTMM) - the Dutch
public-private partnership committed to the research and development of new
techniques for the diagnosis and treatment of major diseases - today
announced that eight new research projects will receive funding from the
CTMM. It means that almost 250 million Euros have now been allocated to
Netherlands-based translational projects that could radically improve patient
outcomes for diseases such as Alzheimer's, rheumatoid arthritis, sepsis,
cardiovascular disorders and the most important forms of cancer.
Related News
Sirius XM passing along $2 performance fees to subscribersSeptember 30th, 2009 Sirius XM passing $2 royalty fees to subscribersSirius XM listeners are getting $2 fees added to their monthly satellite radio bills, in what amounts to a sneaky price increase. Sirius XM Radio Inc., whose talk show celebrities include Howard Stern, is passing along performance royalty fees paid to singers, musicians and recording companies.
Panjab University signs pact with Australian varsityJanuary 13th, 2009 CHANDIGARH - Panjab University (PU) signed an agreement on academic collaboration with the University of Western Australia (UWA) Wednesday. 'This collaboration will include both the staff and student exchange programmes and will facilitate the exchange of technical knowhow between the two institutions,' said B.S.
At least five Somali pirates drown with ransomJanuary 9th, 2009 NAIROBI - At least five Somali pirates drowned with their share of ransom after their boat capsized off the coast of the Horn of Africa nation, reports Saturday said. The pirates had set free Saudi supertanker Sirius Star, which was hijacked two months ago, in exchange for a reported $3 million ransom.
Distinguished economist Dr. Badal Mukhopadhyay joins TERI UniversityMarch 12th, 2009 NEW DELHI - TERI University is honoured to have Dr. Badal Mukhopadhyay as the Professor of Economics.
Somali pirate 'washes ashore with cash'January 12th, 2009 MOGADISHU - The body of a Somali pirate who reportedly drowned soon after receiving a huge ransom has washed ashore with $153,000 in cash, BBC reported Monday. The man was one of a group of pirates who seized the Saudi supertanker Sirius Star in November.
Somali pirates free Saudi oil tankerJanuary 9th, 2009 MOGADISHU - A Saudi oil tanker that was seized by Somali pirates in mid-November in the Indian Ocean has been released, officials and a member of the bandit group confirmed Friday. 'We have released the ship along with the crewmembers.
Six million pounds for Indo-British science collaborationFebruary 2nd, 2009 LONDON - India and Britain Tuesday announced six million pounds of funding for large-scale science and technology collaboration between their universities and institutions. The three collaborations will be funded jointly by Research Councils UK (RCUK), a government-funded body, and the Indian Department of Science of Technology.
Minority teachers underrepresented at theology schools, group aims to reverse courseJune 5th, 2009 More minority teachers needed at theology schoolsNASHVILLE, Tenn. — Minority teachers are underrepresented at theological schools and need more financial help and encouragement to become faculty, according to a prominent group of scholars dedicated to improving religious education.
Neil Diamond 'planning collaboration with Fred Durst'April 8th, 2009 LONDON - Renowned pop legend Neil Diamond may end up matching tunes with Limp Bizkit rocker Fred Durst. The two got in touch using social networking site Twitter.com with Durst approaching the 68-year-old for a collaboration.
Southwest Bancorp announces quarterly dividend of 23.8 centsAugust 28th, 2009 Southwest Bancorp announces quarterly dividendSTILLWATER, Okla. — Southwest Bancorp Inc.
